Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Trial of Ombrabulin (AVE8062) in Combination With Taxane and Platinum in Patients With Non-small Cell Lung Cancer (DISRUPT)

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Sanofi
ClinicalTrials.gov Identifier:
NCT01263886
First received: December 14, 2010
Last updated: December 14, 2012
Last verified: December 2012

December 14, 2010
December 14, 2012
January 2011
March 2012   (final data collection date for primary outcome measure)
Progression free survival (PFS) [ Time Frame: approximately 1.5 years ] [ Designated as safety issue: No ]
Same as current
Complete list of historical versions of study NCT01263886 on ClinicalTrials.gov Archive Site
  • Overall survival (OS) [ Time Frame: approximately 1.5 years ] [ Designated as safety issue: No ]
  • Objective response rate (OR) [ Time Frame: approximately 1.5 years ] [ Designated as safety issue: No ]
Same as current
Not Provided
Not Provided
 
Trial of Ombrabulin (AVE8062) in Combination With Taxane and Platinum in Patients With Non-small Cell Lung Cancer
A Multinational, Randomized, Double Blind, Controlled Phase II Trial of Ombrabulin With Taxane and Platinum Combination Administered Every Three Weeks, in First Line Treatment of Patients Metastatic Non-small Cell Lung Cancer

Primary Objective:

  • To demonstrate progression free survival (PFS) improvement for ombrabulin compared to placebo, in combination with taxane and platinum, as first line treatment for patients with metastatic non-small cell lung cancer (NSCLC).

Secondary Objective:

  • To determine overall survival (OS), overall response rate (ORR) according to Response Evaluation Criteria In Solid Tumors (RECIST) criteria, safety, and evaluate potential biomarkers, pharmacokinetic (PK) analysis of ombrabulin and its main metabolite, RPR258063, using a population approach.

Patients will be treated for a maximum of 6 cycles (21 days each), in the absence of unacceptable toxicity or disease progression or consent withdrawal. All patients will be followed for disease progression documentation and for patient status until up to one year after the primary analysis cutoff date.

Interventional
Phase 2
Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Investigator)
Primary Purpose: Treatment
Non-small Cell Lung Cancer
  • Drug: ombrabulin (AVE8062)

    Pharmaceutical form:solution

    Route of administration: intravenous

  • Drug: placebo

    Pharmaceutical form:solution

    Route of administration: intravenous

  • Experimental: AVE8062 and combination

    Day 1: AVE8062

    Day 2: docetaxel followed by cisplatin or paclitaxel followed by carboplatin

    Intervention: Drug: ombrabulin (AVE8062)
  • Placebo Comparator: Placebo

    Day 1: placebo

    Day 2: docetaxel followed by cisplatin or paclitaxel followed by carboplatin

    Intervention: Drug: placebo
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
176
October 2012
March 2012   (final data collection date for primary outcome measure)

Inclusion criteria:

  • Histologically proven squamous metastatic non-small cell lung cancer (stage IV, according to Tumor Nodes Metastasis (TNM) classification seventh edition)
  • Patients with measurable disease, Response Evaluation Criteria In Solid Tumors (RECIST) criteria (version 1.1)
  • Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1

Exclusion criteria:

  • Prior chemotherapy, immunotherapy or targeted therapy for lung cancer disease (including adjuvant/neoadjuvant therapy)
  • History of brain metastases, uncontrolled spinal cord compression, or carcinomatous meningitis
  • History of another neoplasm. Adequately treated basal cell or squamous skin cancer, or in situ cervical cancer, or any other cancer from which the patient has been disease-free for >5 years are allowed
  • Participation in another clinical trial and any concurrent treatment with any investigational drug within 30 days prior to randomization
  • Acquired immunodeficiency syndrome (AIDS-related illness) or known human immunodeficiency virus (HIV) disease requiring antiretroviral treatment
  • Any severe acute or chronic medical condition, which could impair the ability of the patient to participate in the study or interfere with interpretation of study results
  • Pregnant or breast-feeding woman. Positive serum or urine pregnancy test prior to randomization
  • Patient with reproductive potential (Male/Female) who do not agree to use accepted and effective method of contraception during the study treatment period and for at least 3 months after the completion of the study treatment. The definition of "effective method of contraception" will be based on the investigator's judgment
  • Inadequate organ function
  • Pre-existing peripheral neuropathy > grade 1 according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) V.4.03
  • Pre-existing hearing impairment > grade 2
  • Known hypersensitivity due to taxanes and /or polysorbate 80 or any other compound of the study drug combination
  • Other serious illness or medical conditions such as (but not restricted): Active infection, Superior vena cava syndrome, Pericardial effusion requiring intervention (drainage)
  • Documented medical history of myocardial infarction, documented angina pectoris, arrhythmia especially severe conduction disorder such as second or third-degree atrioventricular block, stroke, or history of arterial or venous thromboembolism within the past 6 months still requiring anticoagulants.
  • Uncontrolled hypertension within 3 months prior to study treatment or patient with organ damage related to hypertension.
  • Patient with Left Ventricular Ejection Fraction (LVEF) value lower than institution inferior normal limit, evaluated by echocardiography or angiocardiography
  • 12-lead Electrocardiogram (ECG): Infarction Q-wave, ST segment depression or elevation ≥1 mm in at least 2 contiguous leads
  • History of gross hemoptysis (i.e. 1/2 teaspoon of red blood or more per episode) within the past 1 month.
  • Has non-squamous NSCLC(adenocarcinoma/large cell or other)

The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

Both
18 Years and older
No
Contact information is only displayed when the study is recruiting subjects
United States,   Australia,   Chile,   Croatia,   France,   Germany,   Italy,   Korea, Republic of,   Poland,   Romania,   Russian Federation,   Serbia,   Ukraine
 
NCT01263886
EFC10259, 2010-019384-11, U1111-1115-3677
No
Sanofi
Sanofi
Not Provided
Study Director: Clinical Sciences & Operations Sanofi
Sanofi
December 2012

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP